Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
Eleni Panagioti(Brigham and Women's Hospital), Evanthia Galanis(The University of Texas at San Antonio Health Science Center)
Cited by 61
Related Papers
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
|Journal of Clinical Oncology|2005|695